SLC5A2 and Hypoglycemia: No significant differences were found for hypovolemia, renal impairment or failure, fracture, diabetic ketoacidosis (DKA), amputation, and severe hypoglycemia between the SGLT-2 inhibitor and the placebo groups.<h4>Conclusion</h4>In patients with T2DM, dapagliflozin was associated with an increased risk of RTIs, pollakiuria, and UTIs.